베이징은 눈을 깜빡이지 않는다

THE DAILY H.E.A.T. Torching Wall Street's Obsolete Playbook. Delivered straight to your inbox 5 days a week. Subscribe Home Posts Beijing Is Not Blinking Beijing Is Not Blinking Apr 23, 2026 I've been a trader and investor for 44 years. I left Wall Street long ago—-once I understood that their obsolete advice is designed to profit them, not you. Today, my firm manages around $4 billion in ETFs, and I don't answer to anybody. I tell the truth because trying to fool investors doesn't help them, or me. In Daily H.E.A.T. , I show you how to Hedge against disaster, find your Edge, exploit Asymmetric opportunities, and ride major Themes before Wall Street catches on. Table of Contents H.E.A.T. News vs. Noise: What's Moving Markets Today ETF News In Case You Missed It H.E.A.T. Wall Street is treating the trade war like a pause. It's a permanent condition. The U.S. and China have entered a managed rivalry with no off-ramp. Here's the investment map. THE TELL Before I lay out the full picture, I want to show you something. The Trump administration is scheduled to meet Xi Jinping in Beijing on May 14th. Analysts and market commentators are watching for breakthroughs on tariffs, rare earths, Boeing orders, soybeans. The usual suspects. Here's what's actually on the table — and what isn't. BEIJING SUMMIT AGENDA — WHAT'S ON THE TABLE AND WHAT ISN'T ON THE TABLE: Soybean purchases, rare earth access, FDI terms, Boeing orders, auto tariffs, Section 301 port fees, a proposed "Board of Trade" NOT ON THE TABLE: AI chip export restrictions, Taiwan defense commitments, currency manipulation, industrial subsidy reform THE TELL: When two countries refuse to discuss their biggest structural disputes, they aren't managing rivalry. They're managing the clock. That list — and the gap between the two columns — is the most important thing you can know about U.S.-China policy right now. Markets are pricing this summit like a dealmaking moment. It isn't. What it actually represents is the formalization of something that's been building since Trump and Xi last met in Busan, South Korea in October 2025. That meeting — which the foreign policy crowd has taken to calling the "Busan Truce" — wasn't a reset. It was a 90-day pause designed to halt escalation while both sides hardened their structural positions. The tariff wall didn't come down after Busan. It became the floor. The tech restrictions didn't loosen. They got more bureaucratically complex. The language on Taiwan shifted — subtly, quietly, in ways that set off alarm bells in Taipei and sent a very different signal to Beijing. The Busan Truce is holding. That's the good news. The bad news is what it's holding in place. "Tariffs are no longer leverage. They are policy architecture. The floor isn't moving." 43% China's share of global antibiotic & pharma ingredient exports (WIPO/WTO/OECD) 90% Iran's oil exports flowing to China 25 yrs China-Iran strategic partnership signed 2021 $0 Progress on AI chips, Taiwan, or currency at Busan Sources: WIPO, WTO, OECD, TD Cowen Washington Research Group (April 2026) THE MAP: A THREE-FRONT CONTEST Let me give you the framework. This isn't a trade war. It's three wars running simultaneously — and each one maps directly to a different layer of your portfolio. Front One: Trade. The tariff architecture is permanent. The baseline rate isn't coming down — it's the new floor, and any escalation above it triggers Chinese retaliation. The Phase One promises from Trump 1.0 went unmet. New Section 301 investigations are open. Every future negotiation happens inside this structure, not outside it. Front Two: Technology. Export controls, licensing regimes, and new AI "diffusion rules" are adding friction to the most important growth market in American technology. Following the Beijing summit, the Commerce Department is expected to require licenses before Nvidia and AMD can sell their most advanced GPUs overseas — closing the loophole that let overseas cloud providers lease remote GPU access to Chinese hyperscalers. The intent is to signal toughness without breaking the business model. The effect is a permanent ceiling on the growth slope. Front Three: Security. U.S. military posture in INDOPACOM is hardening. The focus is deterrence — preventing China from achieving regional hegemony — and protecting the Western Hemisphere from Chinese influence from Mexico to the Panama Canal. This posture doesn't make headlines every week. But it shows up in every defense budget, every procurement cycle, and every arms delivery schedule for the next decade. That is what managed rivalry means in practice: escalation with guardrails — and no off-ramp. THE RARE EARTH VETO There's a reason the MATCH Act — a bipartisan bill that would ban sales of critical semiconductor equipment to China — is likely to stall in Congress despite real support from both parties. China deployed rare earth export controls seven separate times in 2025. The first two rounds — hitting tungsten, tellurium, bismuth, molybdenum, indium, and a second wave of medium/heavy rare earths including dysprosium and terbium — went into immediate effect. Five more rounds issued in October 2025, covering lithium-ion battery supply chains, mining equipment, and even items manufactured abroad using Chinese-origin materials, are technically paused but still on the books. That pause is the veto. Beijing can flip that switch anytime Washington overreaches on semiconductor equipment controls. The math is simple: the U.S. processes virtually none of its own critical minerals at scale. Until that changes, China holds a functional veto over American tech sanctions policy. The practical implication for the MATCH Act: it's less likely to pass than the bipartisan support suggests, because the rare earth retaliation calculus is too painful. The legislation may linger as a threat — and that threat alone has investment implications — but full passage is a low-probability outcome unless trade conditions deteriorate sharply. That same logic makes domestic rare earth producers and processors one of the most structurally advantaged investment positions in the current environment. Not because of any single policy move. Because of the policy architecture. THE SLEEPER FRONT: BIOSECURITY Everyone in this business understands the semiconductor story. Far fewer understand what is quietly becoming the second battlefield of the decoupling: pharmaceuticals and life sciences. China is the single largest exporter of antibiotics and unfinished pharmaceutical ingredients in the world. According to data from the WIPO, WTO, and OECD, it controls roughly 43% of that market. The entire United States accounts for just 4%. India — the country most often cited as America's pharmaceutical backstop — holds approximately 9%. Washington has noticed. Legislation restricting U.S. federal contracts with certain Chinese biotech firms is gaining bipartisan traction. The push to pull American drug supply chains away from Chinese active pharmaceutical ingredient (API) manufacturers is now an active policy priority, not a fringe concern. For investors, the translation is straightforward: this is government-directed demand for domestic pharmaceutical manufacturing capacity. That's not a cyclical trade — it's a decade-long structural allocation. The plays are domestic CDMOs (contract drug manufacturers), specialty chemical producers with non-China API sourcing, and any company building the physical infrastructure of an American pharmaceutical supply chain. The biosecurity angle doesn't make the front page because it moves slowly. That's exactly why it's worth owning early. "China controls roughly 43% of global antibiotic exports. The U.S. accounts for 4%. Washington has noticed." THE TAIWAN WILDCARD: A DASHBOARD, NOT A FORECAST I want to be precise about Taiwan, because imprecision on this topic is where investors get burned. I'm not predicting a Taiwan conflict. Neither is anyone I respect. What I am saying is that the market is pricing in zero Taiwan risk premium on a set of assets — primarily TSMC and the AI hardware stack that depends on it — that would reprice violently if that calculus changed. Here is the thing worth watching: the language is moving. The Trump administration has quietly shifted from saying the U.S. "opposes" unilateral changes to Taiwan's status, to saying it "does not support" them. That is a two-word change. In diplomatic practice, it is a canyon. The first formulation is a commitment. The second is a preference. Taipei has noticed. Beijing has noticed. Wall Street, for the most part, has not. TAIWAN RISK DASHBOARD — WHAT TO WATCH (NOT PREDICTIONS) Official language: Watch for any further softening in State/DoD statements about U.S. commitments to Taiwan Strait activity: Unusual PLA naval exercises or air incursions beyond baseline patterns Arms delivery schedules: Acceleration or delay signals political temperature Export control escalation: New restrictions on advanced packaging or supply chain nodes near Taiwan Allied posture shifts: Japan, Australia, and Philippines basing/deployment headlines Semiconductor licensing: Any change to TSMC's U.S. export license terms NEXT 30–60 DAYS: CATALYST CALENDAR WHAT'S COMING AND WHAT TO WATCH FOR May 14-15: Trump-Xi Beijing Summit — watch the joint statement language on Taiwan, rare earths, and any AI chip carve-outs Post-Summit (May/June): Commerce Dept expected to issue new AI Diffusion Rule — licensing requirements for Nvidia/AMD overseas GPU sales Ongoing: October 2025 rare earth controls remain paused — any activation is an immediate supply chain shock Ongoing: MATCH Act legislative calendar — bipartisan support is real, passage odds are low; watch for committee movement Ongoing: BIOSECURE Act momentum — committee hearings and pharma industry lobbying activity signal policy timeline Ongoing: Section 301 port/ship fees — suspended for one year, renegotiation window opens late 2026 WINNERS — Structural Beneficiaries of the Managed Rivalry Company (Ticker) Thesis Front MP Materials (MP) Domestic rare earth mining and processing. Only operating rare earth mine in the U.S. Policy architecture demands what they produce regardless of summit outcomes. Trade Front — materials sovereignty Energy Fuels (UUUU) Uranium plus rare earth recovery. U.S. government extended a 15-year heavy rare earth offtake. Dual tailwind from nuclear energy AND mineral decoupling. Trade Front — government-backed demand floor Booz Allen Hamilton (BAH) Defense and intelligence contractor. INDOPACOM posture hardening generates long-duration government revenue that doesn't depend on political cycle. Security Front — deterrence procurement RTX / Raytheon (RTX) Precision munitions, missile defense, electronic warfare. All directly relevant to Taiwan deterrence posture. Multi-year procurement cycles insulated from summit noise. Security Front — deterrence procurement Domestic CDMOs / specialty pharma Pharmaceutical manufacturing reshoring is government-directed demand. Companies building domestic API and drug manufacturing capacity are the picks-and-shovels play. Trade Front — supply chain substitution Palantir (PLTR) Defense tech and intelligence analytics. Elevated INDOPACOM activity and domestic data infrastructure buildout are structural tailwinds. Security Front — tech-enabled deterrence PRESSURE POINTS — Margin or Positioning Risk Company (Ticker) Pressure Point Watch For Nvidia (NVDA) AI Diffusion licensing rules post-summit add approval friction to overseas GPU sales. Not an earnings killer — a growth ceiling. The slope gets capped, not broken. Rule implementation speed; ally licensing terms Applied Materials (AMAT) MATCH Act headline risk is real even if passage odds are low. Any semiconductor equipment export tightening hits China revenue directly and without warning. Congressional escalation; rare earth counter-retaliation TSMC ADR (TSM) Taiwan language shift is subtle but meaningful. The market prices zero risk premium on geopolitical language that is quietly moving in the wrong direction. State/DoD language; Strait activity; allied posture iShares MSCI China (MCHI) Capital markets separation is a contingent — not base-case — risk. But forced delistings are the deterioration tool of choice if negotiations break down. Geopolitical flashpoint; MATCH escalation; bilateral tone Danaher / Thermo Fisher (DHR / TMO) Life sciences instrument exposure to Chinese research market faces BIOSECURE-style procurement restrictions as decoupling accelerates. BIOSECURE Act momentum; Chinese research budget policy BEAR CASE — What Would Break This Framework? 1. Taiwan incident: Any kinetic event — even a blockade drill that escalates — reprices every AI/semiconductor name overnight. Zero risk premium means maximum downside on surprise. 2. Rare earth controls fully activated: If Beijing lifts the October 2025 pauses, battery, defense, and EV supply chains face acute 6-12 month disruption with no domestic substitute at scale. 3. MATCH Act passes: Low probability but non-zero. If semiconductor equipment controls go live, AMAT, Lam Research, and KLA face China revenue cliffs in a single legislative event. 4. Capital markets rupture: Forced Chinese delistings from U.S. exchanges are the financial deterioration tool. If U.S.-China relations break down, this is the mechanism that gets deployed. 5. Iran wildcard: 90% of Iran's oil flows to China under a 25-year strategic partnership signed in 2021. A U.S.-Iran war resolution that severs that supply changes China's energy calculus — and its willingness to negotiate on everything else. FIVE THINGS TO TAKE AWAY 1. This is managed rivalry, not reconciliation. The Busan Truce stopped the bleeding — it didn't close the wound. Policy is hardening structurally while stabilizing tactically. Price assets accordingly. 2. The three-front map is your portfolio framework. Trade policy feeds rare earth and materials plays. Tech policy feeds semiconductor and AI infrastructure positioning. Security posture feeds defense procurement. Each front has its own timeline and its own beneficiaries. 3. Biosecurity is the sleeper trade of the cycle. Pharmaceutical supply chain reshoring is a decade-long, government-directed demand story that most China coverage ignores entirely. Find the domestic manufacturing picks and shovels before the BIOSECURE Act makes them obvious. 4. Taiwan is the tail risk everyone is underweighting. The language is moving. The market isn't pricing it. A two-word diplomatic shift is not a prediction of conflict — it is a signal that ambiguity is being deliberately expanded. That's worth a small, explicit risk position. 5. Rare earth controls are the real veto. Not tariffs, not summits, not photo ops. As long as the U.S. cannot process its own critical minerals at scale, China holds a functional override on the most aggressive American technology sanctions. Domestic rare earth producers aren't just a trade — they're a geopolitical necessity. Space Exposure Designed For Potential Weekly Payouts The space economy is no longer just a government program — it's becoming part of a global industry that is gradually advancing. But why view long-term growth as the only potential path forward? SPCI seeks to offer approximately 100% concentrated exposure to the space industry while striving to generate weekly income through a disciplined put credit spread options strategy. Gain exposure to the "final frontier" and a potential weekly distribution while you wait for the theme to play out. Discover SPCI. Distributor: Foreside Fund Services | Investing involves risk including possible loss of principle. News vs. Noise: What's Moving Markets Today As I watch market's give back some of yesterday's gains and oil moving up, with oil stocks also moving up, what I told Schwab yesterday still holds..... Everyone is going to be talking about TSLA earnings today, but the real story is SK Hynix… THE NOISE SK Hynix dropped a quarter for the ages — revenue up 198%, net income up 398%, 72% operating margins — and the stock closed flat. Traders yawned. After an 88% run in 2026, even a record-breaking print can't clear the bar anymore. That's the headline everyone will be talking about today: "Hynix beats big and does nothing." Ignore it. A flat tape after a monster beat in an already-extended name isn't a warning sign. It's just what happens when expectations are priced for perfection. THE SIGNAL What actually matters here is buried in the CFO's comments. Demand is set to outpace supply for at least three years. Capex is set to "increase significantly" this year. They've got $23 billion in cash — roughly 5% of market cap — and they're planning a U.S. listing to fund even more expansion. That's not a company managing a cyclical bounce. That's a company building infrastructure for a multi-year supercycle. HBM leadership into Nvidia's Vera Rubin platform is a structural moat, not a product cycle. The read-through for the rest of the WFE and memory ecosystem — LRCX, ICHR, MU — is still firmly intact. JPMorgan's price target implies 26% upside from here. The story isn't over. It's just getting expensive to believe. Expect some things in this area from us over the next couple of months. What Iran Tells Us About UFO Disclosure When governments confront unknown threats in their airspace, defense budgets surge and the same aerospace and surveillance companies move hardest. On March 2nd, Northrop jumped 6% and Lockheed 3.3% on the Iran news — and President Trump has since ordered the formal release of government UAP files, with the Pentagon confirming compliance. So if a conventional conflict can move these stocks this fast, what happens when the bigger story breaks? See the UFOD holdings: [thetruthisoutthereufod.com ETF News A Stock I'm Watching $BABA ( ▼ 3.94% ) Keeping with the China theme. Nice undercut and rally at the beginning of the month. Bulls want to see the 50 day moving average hold here. In Case You Missed It Was a pleasure to join the Trader Club Sunday night to talk AI and option income…. The H.E.A.T. (Hedge, Edge, Asymmetry and Theme) Formula is designed to empower investors to spot opportunities, think independently, make smarter (often contrarian) moves, and build real wealth. The views and opinions expressed herein are those of the Chief Executive Officer and Portfolio Manager for Tuttle Capital Management (TCM) and are subject to change without notice. The data and information provided is derived from sources deemed to be reliable but we cannot guarantee its accuracy. Investing in securities is subject to risk including the possible loss of principal. Trade notifications are for informational purposes only. TCM offers fully transparent ETFs and provides trade information for all actively managed ETFs. TCM's statements are not an endorsement of any company or a recommendation to buy, sell or hold any security. Trade notification files are not provided until full trade execution at the end of a trading day. The time stamp of the email is the time of file upload and not necessarily the exact time of the trades. TCM is not a commodity trading advisor and content provided regarding commodity interests is for informational purposes only and should not be construed as a recommendation. Investment recommendations for any securities or product may be made only after a comprehensive suitability review of the investor's financial situation.© 2026 Tuttle Capital Management, LLC (TCM). TCM is a SEC-Registered Investment Adviser. All rights reserved. Keep Reading Apr 15, 2026 • 20 min read The Great Data Center Mirage: Wall Street Is Counting Gigawatts That Will Never Exist Apr 13, 2026 • 20 min read Value Investing Is Dead. Meet HALO Apr 17, 2026 • 9 min read The Weight Loss War Just Got a New Front, and One Stock Has the High Ground. View more